Dermatomyofibromas harbor PDGFRB mutations - another tyrosine kinase-driven neoplasm

Uta Flucke1,2, Laura S Hiemcke-Jiwa3,4, Joost M van Gorp5

  • 1Department of Pathology, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. uta.flucke@radboudumc.nl.

Insights

Activating mutations in Platelet-Derived Growth Factor Receptor Beta (PDGFRB) drive dermatomyofibromas, a type of benign skin tumor. These PDGFRB mutations were identified in most investigated cases, linking them to tyrosine kinase-driven neoplasms.

Area of Science:

  • Oncology
  • Dermatology
  • Genetics

Background:

  • Platelet-Derived Growth Factor Receptor Beta (PDGFRB) is a receptor tyrosine kinase implicated in mesenchymal neoplasms.
  • Alterations in PDGFRB are known drivers in various tumors, including pericytic tumors and sarcomas.

Purpose of the Study:

  • To investigate the presence and type of PDGFRB mutations in dermatomyofibromas.
  • To determine if dermatomyofibromas are associated with tyrosine kinase-driven alterations.

Main Methods:

  • Seven dermatomyofibroma cases were analyzed.
  • Histomorphological and immunohistochemical analyses were performed.
  • DNA or RNA sequencing was used to identify PDGFRB mutations.

Main Results:

  • PDGFRB activating mutations were found in 6 out of 7 dermatomyofibromas.
  • Mutations were located in exon 12 (juxtamembrane domain) or exon 14 (tyrosine kinase domain).
  • Neoplasms showed characteristic myofibroblastic morphology and expressed SMA and CD34.

Conclusions:

  • Dermatomyofibromas harbor PDGFRB activating mutations.
  • These findings classify dermatomyofibromas within the spectrum of tyrosine kinase-driven neoplasms.
  • The study highlights the importance of molecular profiling in understanding benign skin tumors.